Cipla (CIPLA.NS) Financial Analysis & Valuation | Quarter Chart
Cipla Limited, together with its subsidiaries, manufactures and sells pharmaceutical products in India, the United States, South Africa, and internationally. The company offers active pharmaceutical ingredients; and formulations in various therapeutic areas, such as MI, angina, heart failure, hypert... more
Cipla Limited, together with its subsidiaries, manufactures and sells pharmaceutical products in Ind... more
Company facts
Reported company information and share structure.
Company
Share structure
| Market Cap | $10.90B | Exchange | NSE |
| Sector | Healthcare | Industry | Drug Manufacturers - General |
| Country | IN | CEO | Achin Gupta |
| IPO Date | 1996-01-01 | CAGR | 13.2% |
| Employees | 31,369 | Website | www.cipla.com |
| Div. Yield | 2.31% | Payout Ratio | 33% |
| Buy Back Yield | — | Total Yield | 2.31% |
CIPLA.NS chart loading...
Key metrics
Reported fundamentals and market-derived technical indicators.
Fundamentals
Technicals
| EV | $9.22B | P/E | 31.35 | Forward P/E | 20.71 | PEG | -0.81 |
| P/S | 3.69 | P/B | 2.99 | P/CF | 76.36 | P/FCF | 151.12 |
| Sales | $2.91B | Sales 1Y | 2.87% | Sales 3Y | 24.66% | Sales 5Y | 46.71% |
| EPS | $0.43 | EPS 1Y | -26.43% | EPS 3Y | 38.33% | EPS 5Y | 61.13% |
| Sales QoQ | -6.06% | EPS QoQ | -17.94% | Sales QoQ Avg | -0.42% | EPS QoQ Avg | -14.4% |
| Gross Margin | 48.23% | Operating Margin | 16.8% | Profit Margin | 13.83% | ROCE | 13.29% |
| ROA | 9% | ROE | 12% | Altman Z Score | 11.1 | Piotroski Score | 4 |
| Current Ratio | 3.44 | Quick Ratio | 2.5 | Cash Ratio | 0.15 | Op. CF Ratio | — |
| Debt/Equity | 0.02 | Debt/Assets | 0.01 | Lt Debt/Equity | 0.01 | Lt Debt/Cap. | 0 |
| Intrst Cov. | 86.67 | Inventory Turnover | 2.2 | Asset Turnover | 0.66 | Receivables Turnover | 4.67 |
| Enterprise Value | $9.22B | P/E Ratio | 31.35 |
| Forward P/E | 20.71 | PEG Ratio | -0.81 |
| P/S Ratio | 3.69 | P/B Ratio | 2.99 |
| P/CF Ratio | 76.36 | P/FCF Ratio | 151.12 |
| EPS | $0.43 | EPS Growth 1Y | -26.43% |
| EPS Growth 3Y | 38.33% | EPS Growth 5Y | 61.13% |
| Revenue Growth 1Y | 2.87% | Gross Margin | 48.23% |
| Operating Margin | 16.8% | Profit Margin | 13.83% |
| ROE | 12% | ROA | 9% |
| ROCE | 13.29% | Current Ratio | 3.44 |
| Quick Ratio | 2.5 | Cash Ratio | 0.15 |
| Debt/Equity | 0.02 | Interest Coverage | 86.67 |
| Altman Z Score | 11.1 | Piotroski Score | 4 |
Cipla (CIPLA.NS) valuation & financials
Cipla (CIPLA.NS) has a market capitalization of $10.90B and trades at a price-to-earnings ratio of 31.4. It operates in the Healthcare sector (Drug Manufacturers - General).
Cipla's revenue grew +2.9% over the last year.
Cipla's next earnings report is scheduled for October 27, 2026 (provider scheduled date); analysts estimate EPS of $0.12. Check the earnings calendar to see all companies reporting this week.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · Merck (MRK) · UnitedHealth (UNH) · Roche (ROG.SW)